Research Article

Effect of Immunosuppression on Newcastle Disease Virus Persistence in Ducks with Different Immune Status

Lucy W. Njagi,1 Phillip N. Nyaga,1 Lilly C. Bebora,1 Paul G. Mbuthia,1 and Uswege M. Minga2

1 Department of Veterinary Pathology, Microbiology and Parasitology, University of Nairobi, P.O. Box 29053-00625, Kangemi, Kenya
2 Department of Life Sciences, FSTES, African Council for Distance Education—Technical Committee on Collaboration (ACDE-TCC), Open University of Tanzania, P.O. Box 23409, Dar es Salaam, Tanzania

Correspondence should be addressed to Lucy W. Njagi, njagiluc@uonbi.ac.ke

Received 30 November 2011; Accepted 4 January 2012

Academic Editors: A. Mankertz and I. Nsahlai

Copyright © 2012 Lucy W. Njagi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study was carried out to verify the possibility that ducks are sources of Newcastle disease (ND) virus infection for chickens in mixed flocks. Immunosuppressed (IS) and non-immunosuppressed (NIS) birds, at three different antibody levels (medium, low and absent) were used; the titres having been induced through vaccination, and immunosuppression done using dexamethasone. Each of the 3 respective groups was further divided into 2 groups of about 12 ducks each: one challenged with velogenic ND virus; the other not challenged. Selected ducks from all groups had their antibody titres monitored serially using hemagglutination inhibition test, while two birds from each of the challenged groups were killed and respective tissues processed for ND viral recovery, using chicken embryo fibroblasts. In general, antibody titres of IS and NIS challenged ducks were significantly higher than their unchallenged counterparts (P < 0.05). Non-challenged pre-immunised ducks had a progressive decrease in antibody levels; non-immunised ducks did not seroconvert. Newcastle disease virus was isolated from livers and kidneys of the challenged ducks throughout the experimental period; indicating a possibility of viral excretion, especially when the birds are stressed. It, therefore, provides another possible model of viral circulation within mixed flocks.

1. Introduction

Village indigenous birds are constantly exposed to immunosuppressive conditions such as aflatoxicosis and infectious bursal disease virus [1]. In addition, management and ecological factors such as confinement, climatic and seasonal fluctuations, poor feeding, and worm infestations have been associated with stress and reduced immune response [2]. Stressful factors have been reported to cause functional and morphological changes in chickens [3].

In Tanzania, it was observed that Newcastle disease (ND) was a greater problem in villages with ducks [4]. Earlier reports indicated that Newcastle disease virus (NDV) persisted for a long time in a flock of ducks in a village situation in Indonesia [5]. However, the factors leading to shedding of the virus by the carrier ducks are not well documented.

It was hypothesized that immunosuppression of immunised carrier ducks does not influence persistence of NDV in these birds. In this experiment, dexamethasone was used to simulate stress in village indigenous ducks. Thus, the aim of the present study was to determine the effect of immunosuppression on the viral persistence and immune status of ducks. It was designed to simulate field situation where ducks that have varying levels of NDV antibodies undergo immunosuppression in the presence of high NDV challenge.

2. Materials and Methods

2.1. Experimental Birds. One-day-old indigenous ducklings were hatched from the duck flock maintained at the University of Nairobi premises. All the birds were reared in isolation and transferred to experimental units at one year of age. They were wing tagged, tested, and confirmed to be free of NDV and respective antibodies. Water and food were provided ad libitum.

2.2. Inactivated Vaccine and Viral Inoculum. A Kenyan virulent Newcastle Disease virus isolate (vNDV) was obtained from the repository maintained at the University of Nairobi.
Table 1: Groups of ducks used to evaluate the effect of immunosuppression on persistence of Newcastle disease virus under different treatments.

| Antibody grouping of ducks | Group code of ducks | Number of ducks | Treatments |
|----------------------------|--------------------|----------------|------------|
|                            |                    |                | Dexamethasone | vNDV | Vaccination |
| Low antibody level         | 1a                 | 13             | +           | +     | +           |
|                            | 1b                 | 3              | +           | −     | +           |
|                            | 1c                 | 13             | −           | +     | +           |
|                            | 1d                 | 3              | −           | −     | +           |
| Medium antibody level      | 2a                 | 13             | +           | +     | +           |
|                            | 2b                 | 3              | +           | −     | +           |
|                            | 2c                 | 13             | −           | +     | +           |
|                            | 2d                 | 3              | −           | −     | +           |
| Nonimmunized               | 3a                 | 12             | +           | +     | −           |
|                            | 3b                 | 3              | +           | −     | −           |
|                            | 3c                 | 12             | −           | +     | −           |
|                            | 3d                 | 3              | −           | −     | −           |

*: respective treatment administered; −: no treatment; vNDV: velogenic Newcastle disease virus; Groups tabulated as “a”: immunosuppressed and challenged with vNDV; Groups tabulated as “b”: immunosuppressed but not challenged; Groups tabulated as “c”: not immunosuppressed but challenged with vNDV; Groups tabulated as “d” are controls for group c: not immunosuppressed nor challenged; Group 3: comprises unvaccinated controls for the 4 test groups.

and characterized by standard methods [6]. This isolate was used to prepare an inactivated vaccine to immunise the ducks. The inactivated vaccine was prepared by mixing 40% formalin and allantoic fluid with a titer of 2⁹ of vNDV in a ratio of 1:40, that is, formalin to virus [6]. The reparation was kept at room temperature (24°C to 26°C) for 24 hours before use. The inactivation of the virus was confirmed through inoculation of embryonated eggs. All the ducks were vaccinated via an initial dose of 1 mL of the vaccine intramuscularly on the thighs and a booster of 0.5 mL of the same vaccine 16 days later. The live virulent Kenyan Newcastle diseases virus isolate, previously characterized by standard methods [6], was later used to challenge vaccinated and naive ducks.

2.3. Immunosuppression of the Ducks. Dexamethasone (Dexamethasone sodium phosphate and Sodium methyl hydroxybenzoate, Coophavet, France) was used to stress ducks in this study. The respective groups of ducks were injected intramuscularly with the dexamethasone, following the protocol of Corrier et al. [7] modified as follows: the dosage was given at the rate of 2 mg per kilogram of body weight per day for 4 days continuously, then the ducks were rested for 2 days and the injections resumed at the same dosage for 2 more days.

2.4. Experimental Design. Sixty-four ducks were vaccinated with 1 mL of inactivated ND vaccine intramuscularly and 14 days later, they were bled from the brachial vein and sera prepared. They were later boosted with a single dose of 0.5 mL of the ND inactivated vaccine and bled 7 days later. All sera were tested for presence of Newcastle disease antibodies. Seven days after the booster dose, the ducks were divided into two groups, each with 32 birds, namely, low antibody level group (≥1:32) and medium antibody level group (≥1:64). Each group of 32 ducks was further subdivided into 4 minigroups, as follows: (i) immunosuppressed and challenged (1a, 2a), (ii) immunosuppressed only (1b, 2b), (iii) challenged only (1c, 2c), and (iv) not challenged nor immunosuppressed (1d, 2d). Another group (group 3) of 30 nonimmunized ducks were subdivided into 4 groups. Groups 3a and 3c had 12 ducks each while 3b and 3d had 3 birds each. Immunosuppression was done before respective groups were inoculated intranasally with 0.2 mL of undiluted amnioallantoic fluids of vNDV having a titer of 1:1024.

Five birds from each of the challenge groups and all the 3 ducks from each control group were sampled throughout the experimental period (28 days). The samples were taken on days 0, 1, 4, 8, 14, and 28-after inoculation (p.i.). Blood for serum was sampled each time from the five ducks in each challenge group, and the three ducks from each of the controls. Further, two ducks from each of the NDV challenged groups were killed serially and brain, kidney, lung, cecal tonsils, liver, and spleen collected separately from each bird. The tissues were processed for ND viral recovery using chicken embryo fibroblasts, while serum samples were tested for NDV-specific antibodies by hemagglutination inhibition (HI) test. Table 1 shows the experimental design used.

2.5. Virus Isolation. Virus recovery from the tissues was carried out in primary chicken embryo fibroblasts as described by OIE [6].

2.6. Serology. Presence of NDV antibody was detected by hemagglutination inhibition test as described by OIE [6].

2.7. Statistical Analysis. Analysis of variance was performed using SAS software (SAS Institute Inc., Cary, NC, USA, 2002-2003) to determine the treatments’ main effects and the
3. Results

3.1. Serological Responses of Ducks under Different Treatments. Immunosuppressed virus-challenged ducks (group 1a) had low mean antibody levels (5.0) up to day 4 after-inoculation (p.i.) compared with day 0 (4.5). Thereafter, there was marked increase (from 4.5 to 7.0) in antibody titers up to 14 days p.i. After day 14 p.i., there was a slight decrease (6.9) in antibody levels up to 28 days p.i. although the levels were still higher than any period between day 0 and 8 p.i. The nonimmunosuppressed virus-challenged group (1c) had a moderate increase (5.0 to 6.0) in antibody levels from day 1 up to day 14 p.i., after which there was a decrease to day 0 level titers by day 28 p.i. The immunosuppressed group (1b) had marked decrease in antibody titers from day 1 to 4 and gradual decrease (5.0 to 3.8) up to day 28 p.i. (Figure 1(a)).

The immunosuppressed virus-challenged group for the medium antibody level ducks (2a) had a gradual decline (6.0 to 5.7) in antibody titers up to day 4 followed by an increase in antibody titers (6.9) up to day 14 p.i. This was followed by a marked decrease (6.1) and by day 28 p.i. the antibody level was almost equal to the day 0 level titers. The nonimmunosuppressed virus-challenged group (2c) showed a slight decrease (from 6.0 to 5.9) in the antibody titer followed by a gradual decrease and then an increase up to the end of the experiment. From day 1 up to day 4 after-inoculation, the immunosuppressed, immunised noninfected (2b) group showed a more rapid decrease (6.0, 5.2, 4.8, 3.7, 2.3, and finally 2.2) to the nonimmunosuppressed controls (2d). In general, all the nonchallenged, but immunized control ducks showed decrease in antibody titers with time (Figure 1(b)).

The immunosuppressed virus-challenged group (3a) had a gradual antibody response (from 0.0 to 6.5) up to the
end of the experimental period. The nonimmunosuppressed virus-challenged group (3c) showed a massive increase (0.0 to 6.6) in antibody levels similar to immunosuppressed virus-challenged group 3a. The group 3c also had a marked decrease (from 6.6 to 4.6) in antibody titres after day 14 p.i. and by 28 days p.i., the titers were quite low. Negative control ducks (3b and d), sampled at the same time, were negative for NDV antibodies (Figure 1(c)).

For days 4, 8, 14, and 28 p.i., antibody titres of the following groups were found to be significantly different (P < 0.05). When considering the antibody levels elicited in the different duck-groups, with respect to their initial antibody levels, both sets (low-antibody group and medium-antibody group), and both the immunosuppressed and non-immunosuppressed ducks showed higher responses in ducks that were challenged with virulent virus than in those that were not challenged. The difference was statistically significant (P < 0.05). All the control naive ducks (groups 3b and 3d) did not seroconvert.

3.2. Isolation of Newcastle Disease Virus from Immunosuppressed and Nonimmunosuppressed Virus-Challenged Duck. On day 1 after inoculation, NDV titers were recorded in liver tissues of group 1a (low-antibody-level group, immunosuppressed and challenged with vNDV) ducks only. On day 4 p.i., high titres of the NDV were recorded in the kidneys (Figure 2(a)). On day 8 p.i., NDV was isolated in the liver, kidneys, caecal tonsils, and lungs of all treatment groups (Figure 2(b)). The highest NDV titers were recorded in the liver and kidney tissues of immunosuppressed medium (2a) and nonimmune (3a) challenged ducks and nonimmunosuppressed, low-antibody-level challenged ducks (1c). No

**Figure 2:** Newcastle disease viral titres in different tissues (liver, kidney, lung, brain, and caecal tonsils [CT]) of ducks in different treatment groups (Grp): (a) on day 4 after inoculation; (b) on day 8 after inoculation; (c) on day 14 after inoculation; (d) on day 28 after inoculation.
NDV was isolated by day 14 p.i. in the brain and spleen from any of the groups.

On day 14 p.i. high NDV titres were recorded from the liver tissues of ducks in all treatment groups. However, titres were recorded in the cecal tonsils only in group 2a on day 14 p.i. and in groups 1a and 1c at day 28 p.i. (Figures 2(c) and 2(d)). Other organs that were positive for NDV were kidneys and cecal tonsils. In addition, the immunosuppressed ducks of groups 1a (low-antibody-level group, immunosuppressed and challenged with vNDV) and 2a (medium-antibody-level group, immunosuppressed and challenged with vNDV) yielded the highest NDV titres as compared to other treatment groups. Newcastle disease virus was recovered from the brain and lung on day 28 p.i from immunosuppressed ducks only (Figure 2(d)).

4. Discussion

There have been comparatively few sequential virological studies on the pathogenesis of ND in ducks and the reported studies involved only fully susceptible chickens [8, 9]. Reports in other studies have documented frequent isolation of virulent NDV from captive caged birds, healthy wild birds, and village chickens [10–12]. In some cases, the ducks expressed clinical ND as a result of confinement that was understood to have induced stress [13]. Our findings indicate that NDV carrier status in nonnatural hosts such as ducks would possibly, under stress, recrudescence virulent virus from sequestered sites in the kidney, liver, and caecal tonsils, leading to virus release in faecal and respiratory exudates. The excreted virus would set up an infectious index case in chickens, thus maintaining NDV endemicity.

Immunosuppression induced by injection of dexamethasone in the three treatments influenced the pattern of antibody response and the NDV recovery rate. The immunosuppressed ducks that had low and medium antibody level showed a decrease in antibody titers up to day 4 after challenge with NDV. The nonimmunosuppressed virus-challenged ducks of low-to-medium antibody level had an increase in antibody titres up to day 14 p.i. The nonimmunized ducks manifested increased antibody titres after day 4 p.i. and had a massive increase in antibody levels as compared to immunosuppressed challenged group. In the present study, the number of immunosuppressed ducks that yielded the ND virus was higher compared to the nonimmunosuppressed ducks. The prechallenge antibody titres also play a major role in the immune response of immunosuppressed birds such that NDV infection of ducks with high viral titres allows virus multiplication making ducks better carriers. The effect of immunosuppression with dexamethasone in ducks is the same as that induced by aflatoxin in chicks with NDV infections [17]. Chickens fed on aflatoxin produced lower antibody levels when compared to the non-aflatoxin-treated ones [17].

The nonchallenged preimmunized ducks had a progressive decrease in antibody levels suggesting that if they were to be exposed to the virus, they could develop clinical disease but instead may remain as virus carriers. The fact that the ducks in these experiments had high levels of antibodies may not necessarily prevent subclinical infection and excretion of virulent virus as supported by other studies elsewhere [18].

Based on these results, it is possible to assume that immunosuppressed ducks carrying NDV are more likely to shed virus under stress than nonimmunosuppressed ducks. Furthermore, the ducks showed progressively declining antibody titres to very low levels making them more susceptible to infection by challenge NDV virus, thus leading to clinical disease and virus excretion. The excreted virus would contaminate the birds’ environment and be transferred to susceptible and other birds. Thus, immunosuppression seems to have epidemiologically significant effects on NDV carrier ducks having varying antibody titer levels.

Acknowledgments

The authors would like to thank J. K. Kibe, Mary Mutune and Ann Munene for technical assistance and Mr. Crispin Matere for data analysis. Professor John E. Olsen is acknowledged for his constructive criticism and advice. This study was funded by the Danish International Development Agency (DANIDA) through the ENRECA project “Productivity and health of smallholder livestock in Eastern Africa.”

References

[1] M. O. Otim, G. Mukiibi-Muka, H. Christensen, and M. Bisgaard, “Aflatoxicosis, infectious bursal disease and immune response to Newcastle disease vaccination in rural chickens,” Avian Pathology, vol. 34, no. 4, pp. 319–323, 2005.
[2] G. Horning, S. Rasmussen, A. Permin, and M. Bisgaard, “Investigations on the influence of helminth parasites on vaccination of chickens against Newcastle disease virus under village conditions,” Tropical Animal Health and Production, vol. 35, no. 5, pp. 415–424, 2003.
[3] S. Graczyk, J. Kuryshko, and J. Madej, “Reactivity of spleen germinall centres in immunized and ACTH-treated chickens,” Acta Veterinaria Brno, vol. 72, no. 4, pp. 523–531, 2003.
[4] IAEA / FAO, “Improving family poultry production in Africa,” Survey Form, International Atomic Energy Agency, Vienna, Austria, 1999.

[5] D. J. Kingston and R. Dharsana, “Newcastle disease virus infection in Indonesian ducks,” Philippines. Journal of Veterinary Medicine, vol. 18, pp. 125–130, 1979.

[6] Office International des Epizooties (OIE), “‘Newcastle disease’ in terrestrial manual of standards for diagnostic tests and vaccines,” 2009, http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.03.14_NEWCASTLE_DIS.pdf.

[7] D. E. Corrier, M. H. Elissalde, R. L. Ziprin, and J. R. DeLoach, “Effect of immunosuppression with cyclophosphamide, cyclosporin, or dexamethasone on salmonella colonization of broiler chicks,” Avian Diseases, vol. 35, no. 1, pp. 40–45, 1991.

[8] N. Wakamatsu, D. J. King, D. R. Kapczynski, B. S. Seal, and C. C. Brown, “Experimental pathogenesis for chickens, turkeys, and pigeons of exotic Newcastle disease virus from an outbreak in California during 2002-2003,” Veterinary Pathology, vol. 43, no. 6, pp. 925–933, 2006.

[9] K. Nakamura, N. Ohtsu, T. Nakamura et al., “Pathologic and immunohistochemical studies of Newcastle Disease (ND) in broiler chickens vaccinated with ND: severe nonpurulent encephalitis and necrotizing pancreatitis,” Veterinary Pathology, vol. 45, no. 6, pp. 928–933, 2008.

[10] D. J. Alexander, “Newcastle disease and other avian paramyxoviruses,” Scientific and Technical Review, office International Epizooties, vol. 19, no. 2, pp. 443–462, 2000.

[11] L. M. Kim, D. J. King, H. Guzman et al., “Biological and phylogenetic characterization of pigeon paramyxovirus serotype 1 circulating in wild North American pigeons and doves,” Journal of Clinical Microbiology, vol. 46, no. 10, pp. 3303–3310, 2008.

[12] L. W. Njagi, P. N. Nyaga, P. G. Mbuthia et al., “Prevalence of Newcastle disease virus in village indigenous chickens in varied agro-ecological zones in Kenya,” Livestock Research for Rural Development, vol. 22, no. 95, 2010.

[13] G. R. Carter, “Paramyxoviridae,” in A Concise Review of Veterinary Virology, G. R. Carter, D. J. Wise, and E. F. Flores, Eds., International Veterinary Information Service, Ithaca, NY, USA, 2005.

[14] S. Gessani, S. McCandless, and C. Baglioni, “The glucocorticoid dexamethasone inhibits synthesis of interferon by decreasing the level of its mRNA,” Journal of Biological Chemistry, vol. 263, no. 16, pp. 7454–7457, 1988.

[15] E. D. Kilbourne, K. M. Smart, and B. A. Pokorny, “Inhibition by cortisone of the synthesis and action of interferon,” Nature, vol. 190, no. 4776, pp. 650–651, 1961.

[16] M. K. Asdell and R. P. Hanson, “Sequential changes in the titer of Newcastle disease virus in tissues—a measure of the defence mechanism of the chicken,” American Journal of Veterinary Research, vol. 21, pp. 128–132, 1960.

[17] M. O. Otim, H. Christensen, G. M. Mukibibi, and M. Bisgaard, “A preliminary study of the role of ducks in the transmission of Newcastle disease virus to in-contact rural free-range chickens,” Tropical Animal Health and Production, vol. 38, no. 4, pp. 285–289, 2006.

[18] H. D. Stone, M. Brugh, and C. W. Beard, “Comparison of three experimental inactivated oil—emulsion Newcastle disease vaccines,” Avian Diseases, vol. 25, no. 4, pp. 1070–1076, 1981.